Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Iloperidone Relapse Prevention in Schizophrenia
NCT01291511Phase 3Completed
- Sponsor
- Vanda Pharmaceuticals Inc.
- Start
- Feb 2011
- Primary completion
- Mar 2014
- Modality
- Small Molecules
- Countries
- 3
01
Overview
Phase 3, randomised, double-blind trial in schizophrenia comparing Iloperidone with Placebo (2 arms). Primary endpoint: Time to Relapse or Impending Relapse at 26 weeks. Started Feb 2011; status: completed.
02
Drugs
iloperidone
03
Conditions
schizophrenia
Beyond the preview
Go deeper on NCT01291511.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT01291511.